Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists
Paul J. Coleman, John D. Schreier, Georgia B. McGaughey, et al.
Bioorganic & Medicinal Chemistry Letters (2010) Vol. 20, Iss. 7, pp. 2311-2315
Closed Access | Times Cited: 18

Showing 18 citing articles:

New and unusual scaffolds in medicinal chemistry
Charles M. Marson
Chemical Society Reviews (2011) Vol. 40, Iss. 11, pp. 5514-5514
Closed Access | Times Cited: 360
Orexin Receptors: Pharmacology and Therapeutic Opportunities
Thomas E. Scammell, Christopher J. Winrow
The Annual Review of Pharmacology and Toxicology (2011) Vol. 51, Iss. 1, pp. 243-266
Open Access | Times Cited: 350
Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia
Christopher D. Cox, Michael J. Breslin, David B. Whitman, et al.
Journal of Medicinal Chemistry (2010) Vol. 53, Iss. 14, pp. 5320-5332
Closed Access | Times Cited: 348
Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist
Christopher J. Winrow, Anthony L. Gotter, Christopher D. Cox, et al.
Journal of Neurogenetics (2011) Vol. 25, Iss. 1-2, pp. 52-61
Closed Access | Times Cited: 255
Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia
Christopher J. Winrow, Anthony L. Gotter, Christopher D. Cox, et al.
Neuropharmacology (2011) Vol. 62, Iss. 2, pp. 978-987
Closed Access | Times Cited: 121
Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties
Paul J. Coleman, John D. Schreier, Christopher D. Cox, et al.
ChemMedChem (2012) Vol. 7, Iss. 3, pp. 415-424
Closed Access | Times Cited: 115
2-Azabicyclo[2.2.1]hept-5-en-3-one: Chemical Profile of a Versatile Synthetic Building Block and its Impact on the Development of Therapeutics
Rohit Singh, Robert Vince
Chemical Reviews (2012) Vol. 112, Iss. 8, pp. 4642-4686
Closed Access | Times Cited: 109
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 1
Nicholas A. Meanwell, Olivier Loiseleur
Journal of Agricultural and Food Chemistry (2022) Vol. 70, Iss. 36, pp. 10942-10971
Closed Access | Times Cited: 45
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 98
The Generation, Detection, and Effects of Reactive Drug Metabolites
Andrew V. Stachulski, Thomas A. Baillie, B. Kevin Park, et al.
Medicinal Research Reviews (2012) Vol. 33, Iss. 5, pp. 985-1080
Closed Access | Times Cited: 84
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2
Nicholas A. Meanwell, Olivier Loiseleur
Journal of Agricultural and Food Chemistry (2022) Vol. 70, Iss. 36, pp. 10972-11004
Closed Access | Times Cited: 27
Measurement, Interpretation and Use of Free Ligand Solution Conformations in Drug Discovery
Charles D. Blundell, Thorsten Nowak, Martin J Watson
Progress in medicinal chemistry (2016), pp. 45-147
Closed Access | Times Cited: 31
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model
Yuzo Iwaki, Akira Ohhata, Shingo Nakatani, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 6, pp. 1335-1341
Open Access | Times Cited: 24
Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat
Paul J. Coleman, John D. Schreier, Anthony J. Roecker, et al.
Bioorganic & Medicinal Chemistry Letters (2010) Vol. 20, Iss. 14, pp. 4201-4205
Closed Access | Times Cited: 27
Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold‐Hopping Approach
Bibia Heidmann, John Gatfield, Catherine Roch, et al.
ChemMedChem (2016) Vol. 11, Iss. 19, pp. 2132-2146
Closed Access | Times Cited: 17
Orexin Receptor Antagonists
Brock T. Shireman, Michael A. Letavic
Elsevier eBooks (2016), pp. 225-279
Closed Access | Times Cited: 1
Metabolic Activation and Associated Drug Toxicity
Thomas A. Baillie
Handbook of Metabolic Pathways of Xenobiotics (2014), pp. 1-18
Closed Access
Suvorexant (Belsomra), The First‐in‐Class Orexin Antagonist for Insomnia
Nadia Ahmad
(2015), pp. 223-242
Closed Access
Page 1

Scroll to top